<DOC>
	<DOCNO>NCT01812122</DOCNO>
	<brief_summary>The purpose study analyze difference blood sugar level glycemic variability sulfonylurea DPP-4 inhibitor group apply CGMS chosen number type 2 DM patient . The investigator also reveal influence drug cardiovascular risk factor measure related biomarkers .</brief_summary>
	<brief_title>Effects Vildagliptine Glimepiride Glucose Variability</brief_title>
	<detailed_description>We enroll patient type 2 DM uncontrolled glucose level Metformin monotherapy 1000mg /day ( HbA1C 7 % ) . Before drug administration , conduct basal lab study include CGMS . After 3 month random administration vildagliptin glimepiride , check CGMS , glucose level , CV biomarkers , estimate hypoglycemic index . We replace drug 3 month , conduct measurement . No wash-out period necessary since result variable measure 3 month administration different drug .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>type 2 DM uncontrolled glucose level Metformin monotherapy 1000mg /day ( HbA1C 7 % ) . Provided tolerance metformin poor , enrollment patient low dose metfomrin open . never prescribe test drug , sulfonylurea DPP4 inhibitor/GLP1 analogue 3 month apply CGMS liver function abnormality renal function abnormality kind disease , operation , medical treatment affect glucose level</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>